Xing Qin

3.2k citations
65 papers · 2.3k indexed · 2 hit papers · h-index 27
    • Cancer-related molecular mechanisms research 11
    • MicroRNA in disease regulation 10
    • RNA modifications and cancer 12
    • RNA Research and Splicing 6
    • Cancer-related gene regulation 5
    • Extracellular vesicles in disease 5
    • Angiogenesis and VEGF in Cancer 4
  • Genetics top 10%
    • Mesenchymal stem cell research 7
  • Oncology top 10%
  • Immunology top 10%

Xing Qin

63 papers receiving 2.3k citations

Hit Papers

FUNDC1 interacts with GPx4 to govern...1182019202620212023100200300

Peers

Xing Qin
Comparison fields: 5 of 120
  • Cancer Research 901
  • Molecular Biology 1.6k
  • Genetics 143
  • Oncology 367
  • Immunology 224
Replace Xudong Wang with:
Xudong Wang China
Yuxian Song China
Wiktoria Maria Suchorska Poland
Kyoko Hida Japan
Xiaolong Xu China
Delphine Javelaud France
Bin Zhu China
Heyu Zhang China
Li Peng China
Xing Qin relative to Xudong Wang China Xudong Wang's profile →
Citations per field
00.5×1.6×
Xudong Wang · 1×
Citations per year

Countries citing papers authored by Xing Qin

Since Specialization
Citations

This map shows the geographic impact of Xing Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xing Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xing Qin more than expected).

Fields of papers citing papers by Xing Qin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xing Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xing Qin. The network helps show where Xing Qin may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Xing Qin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Xing Qin Line = papers co-authored together Xing Qin links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20251
3 20244
4 20243
5 20231
6 202312
7 20219
8 20206
9 20206
10 2018141
11 20183
12 201753
13 201774
14 201693
15 20158
16 201435
17 201450
18 201350
19 201399
20 20128

About Xing Qin

Xing Qin is a scholar working on Cancer Research, Otorhinolaryngology and Genetics, having authored 65 papers that have together received 2.3k indexed citations. Recurring topics across this work include RNA modifications and cancer (12 papers), Cancer-related molecular mechanisms research (11 papers), MicroRNA in disease regulation (10 papers), Mesenchymal stem cell research (7 papers), RNA Research and Splicing (6 papers), Cancer-related gene regulation (5 papers), Extracellular vesicles in disease (5 papers) and Angiogenesis and VEGF in Cancer (4 papers). The work is most often cited by research in Cancer Research (901 citations), Molecular Biology (1.6k citations) and Genetics (143 citations). Xing Qin has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Jianjun Zhang, Ming Yan, Qin Xu, Wantao Chen, Xueqin Zhu, Jianbo Shi, Wantao Chen, Xiaoning Wang, Haiyan Guo and Jin Yu.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026